

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C.

OMB APPROVAL


OMB Number: 3235-0076

Expires: August 31, 2015

Estimated Average burden hours per response: 4.0

1. Issuer's Identity	
CIK (Filer ID Number) Previous Name(s) None	Entity Type
0001498382 Berry Only Inc.	© Corporation
Name of Issuer	C Limited Partnership
DelMar Pharmaceuticals, Inc.	C Limited Liability Company
Jurisdiction of Incorporation/Organization	C General Partnership
NEVADA	C Business Trust
Year of Incorporation/Organization	C Other
Over Five Years Ago	
Within Last Five Years (Specify Year)	
C Vet to Be Formed	

2. Principal Place of Business and Contact Information			
Name of Issuer			
DelMar Pharmaceuticals, Inc.			
Street Address 1	Stre	eet Address 2	
SUITE 720-999 WEST BROADV	VAY		
City	State/Province/Country	ZIP/Postal Code	Phone No. of Issuer
VANCOUVER	BRITISH COLUMBIA, CANADA	V5Z 1K5	(604) 629-5989



Relationship:	Executive Officer	Director	Promoter
Clarification of Respons	se (if Necessary)		
Officer			
Last Name	First Name	M	iddle Name
Praill	Scott		
Street Address 1		Street Address 2	
Suite 720-999 West I	Broadway		
City	State/Province/	Country Z	IP/Postal Code
Vancouver	1		V5Z 1K5
vaneouver		Devilori, Crivilori	V 32 TK3
Relationship:	Executive Officer	Director	Promoter
Clarification of Respons	se (if Necessary)		
Officer			
Last Name	First Name	М	iddle Name
Garner	William		
Street Address 1		Street Address 2	
	Puo admay	Street Address 2	
Suite 720-999 West 1			mm 1.C. 1
City	State/Province/		IP/Postal Code
Vancouver	BRITISH CO	DLUMBIA, CANADA	V5Z 1K5
Relationship:	Executive Officer	Director	Promoter
Clarification of Respons	se (if Necessary)		
Last Name	Et ad Nova	24	iddle Name
Bell	First Name	IVI	
Street Address 1	John	Street Address 2	Δ.
Suite 720-999 West I	Broadway		
<u> </u>	State/Province/	Country 7	IP/Postal Code
Vancouver Vancouver			V5Z 1K5
vancouver	BRITISH CO	LUMBIA, CANADA	132 183
Relationshin:	Executive Officer	□ ✓ Director	Promoter
Relationship:	Executive Officer	Director	Promoter
Relationship:		Director	Promoter

## 4. Industry Group

C Agriculture	Health Care Retailing	
Banking & Financial Services	C Biotechnology	
C Commercial Banking	C Hespitale & Physicians	
C Insurance	Pharmaceuticals	
C Investing	C Other Health Care Computers	
C Investment Banking	C Telecommunications	
C Pooled Investment Fund	C Other Technology	
Other Banking & Financial	Travel	
C Services	Manufacturing C Airlines & Airports	
C Business Services	Real Estate C Lodging & Conventions	
Energy C Coal Mining	C Commercial C Tourism & Travel Services	
C Electric Utilities	C Construction C Other Travel	
C Energy Conservation	C Residential	
C Environmental Services	C Other Real Estate	
C Oil & Gas		
C Other Energy		
5. Issuer Size		
	Appropriate Net Appet Value Descri	
Revenue Range  No Revenues	Aggregate Net Asset Value Range  No Aggregate Net Asset Value	
C \$1 - \$1,000,000	\$1 - \$5,000,000	
C \$1,000,001 - \$5,000,000	C \$5,000,001 - \$25,000,000	
\$5,000,001 - \$25,000,000	\$25,000,001 - \$50,000,000	
© \$25,000,001 - \$100,000,000	C \$50,000,001 - \$100,000,000	
Over \$100,000,000	Over \$100,000,000	
C Decline to Disclose	C Decline to Disclose	
C Not Applicable	Not Applicable	
Not Applicable	Not Applicable	
	and Exclusion(s) Claimed (select all that	
apply)		
Rule 504(b)(1) (not (i), (ii)		
Rule 504(b)(1) (not (i), (ii) or (iii))	Rule 505	
Rule 504(b)(1) (not (i), (ii) or (iii))  Rule 504 (b)(1)(i)		
Rule 504(b)(1) (not (i), (ii) or (iii))	Rule 505	
Rule 504(b)(1) (not (i), (ii) or (iii))  Rule 504 (b)(1)(i)	Rule 505  Rule 506(b)	
Rule 504(b)(1) (not (i), (ii) or (iii))  Rule 504 (b)(1)(i)  Rule 504 (b)(1)(ii)	Rule 505  Rule 506(b)  Rule 506(c)	
Rule 504(b)(1) (not (i), (ii) or (iii))  Rule 504 (b)(1)(i)  Rule 504 (b)(1)(ii)	□ Rule 505 □ Rule 506(b) □ Rule 506(c) □ Securities Act Section 4(a)(5)	
Rule 504(b)(1) (not (i), (ii) or (iii))  Rule 504 (b)(1)(i)  Rule 504 (b)(1)(ii)	□ Rule 505 □ Rule 506(b) □ Rule 506(c) □ Securities Act Section 4(a)(5)	
Rule 504(b)(1) (not (i), (ii) or (iii))  Rule 504 (b)(1)(i)  Rule 504 (b)(1)(ii)	□ Rule 505 □ Rule 506(b) □ Rule 506(c) □ Securities Act Section 4(a)(5)	
Rule 504(b)(1) (not (i), (ii) or (iii))  Rule 504 (b)(1)(i)  Rule 504 (b)(1)(ii)  Rule 504 (b)(1)(iii)  7. Type of Filing	Rule 506(b)  Rule 506(c)  Securities Act Section 4(a)(5)  Investment Company Act Section 3(c)	
Rule 504(b)(1) (not (i), (ii) or (iii))  Rule 504 (b)(1)(i)  Rule 504 (b)(1)(ii)  Rule 504 (b)(1)(iii)  New Notice  Date of First Sale	□ Rule 505 □ Rule 506(b) □ Rule 506(c) □ Securities Act Section 4(a)(5)	
Rule 504(b)(1) (not (i), (ii) or (iii))  Rule 504 (b)(1)(i)  Rule 504 (b)(1)(ii)  Rule 504 (b)(1)(iii)  7. Type of Filing	Rule 506(b)  Rule 506(c)  Securities Act Section 4(a)(5)  Investment Company Act Section 3(c)	
Rule 504(b)(1) (not (i), (ii) or (iii))  Rule 504 (b)(1)(i)  Rule 504 (b)(1)(ii)  Rule 504 (b)(1)(iii)  New Notice  Date of First Sale	Rule 506(b)  Rule 506(c)  Securities Act Section 4(a)(5)  Investment Company Act Section 3(c)	
Rule 504(b)(1) (not (i), (ii) or (iii))  Rule 504 (b)(1)(i)  Rule 504 (b)(1)(ii)  Rule 504 (b)(1)(iii)  New Notice  Date of First Sale	Rule 506(b)  Rule 506(c)  Securities Act Section 4(a)(5)  Investment Company Act Section 3(c)	
Rule 504(b)(1) (not (i), (ii) or (iii)) Rule 504 (b)(1)(i) Rule 504 (b)(1)(ii) Rule 504 (b)(1)(iii) Rule 504 (b)(1)(iii) Amendment  Rule 504 (b)(1)(iii) Rule 504 (b)(1)(iii) Amendment	Rule 506(b)  Rule 506(c)  Securities Act Section 4(a)(5)  Investment Company Act Section 3(c)	
Rule 504(b)(1) (not (i), (ii) or (iii)) Rule 504 (b)(1)(i) Rule 504 (b)(1)(ii) Rule 504 (b)(1)(iii) Rule 504 (b)(1)(iii) Authorized Date of First Sale Amendment  8. Duration of Offering	Rule 506(b)  Rule 506(c)  Securities Act Section 4(a)(5)  Investment Company Act Section 3(c)  2013-01-25  First Sale Yet to Occur	
Rule 504(b)(1) (not (i), (ii) or (iii)) Rule 504 (b)(1)(i) Rule 504 (b)(1)(ii) Rule 504 (b)(1)(iii) Rule 504 (b)(1)(iii) Amendment  Rule 504 (b)(1)(iii) Rule 504 (b)(1)(iii) Amendment	Rule 506(b)  Rule 506(c)  Securities Act Section 4(a)(5)  Investment Company Act Section 3(c)  2013-01-25  First Sale Yet to Occur	
Rule 504(b)(1) (not (i), (ii) or (iii)) Rule 504 (b)(1)(i) Rule 504 (b)(1)(ii) Rule 504 (b)(1)(iii) Rule 504 (b)(1)(iii) Authorized Date of First Sale Amendment  8. Duration of Offering	Rule 506(b)  Rule 506(c)  Securities Act Section 4(a)(5)  Investment Company Act Section 3(c)  2013-01-25  First Sale Yet to Occur	
Rule 504(b)(1) (not (i), (ii) or (iii)) Rule 504 (b)(1)(i) Rule 504 (b)(1)(ii) Rule 504 (b)(1)(iii) Rule 504 (b)(1)(iii) Author 504 (b)(1)(iii)  7. Type of Filing New Notice Date of First Sale Amendment  8. Duration of Offering Does the Issuer intend this offering to last	Rule 506(b)  Rule 506(c)  Securities Act Section 4(a)(5)  Investment Company Act Section 3(c)  2013-01-25  First Sale Yet to Occur	
Rule 504(b)(1) (not (i), (ii) or (iii)) Rule 504 (b)(1)(i) Rule 504 (b)(1)(ii) Rule 504 (b)(1)(iii) Rule 504 (b)(1)(iii) Amendment  7. Type of Filing New Notice Date of First Sale Amendment  8. Duration of Offering Does the Issuer intend this offering to last  9. Type(s) of Securities (	Rule 506(b)  Rule 506(c)  Securities Act Section 4(a)(5)  Investment Company Act Section 3(c)  2013-01-25  First Sale Yet to Occur  The more than one year?  Yes  No	
Rule 504(b)(1) (not (i), (ii) or (iii)) Rule 504 (b)(1)(i) Rule 504 (b)(1)(ii) Rule 504 (b)(1)(iii) Rule 504 (b)(1)(iii) Author 504 (b)(1)(iiii) Author 504 (b)(1)(iiii) Author 504 (b)(1)(iiiii) Author 504 (b)(1)(iiiiiiiiiiiiiiiii	Rule 506(b)  Rule 506(c)  Securities Act Section 4(a)(5)  Investment Company Act Section 3(c)  2013-01-25  First Sale Yet to Occur	

Option, Warra Mineral Property Securities  Acquire Anoth	ant or Other Right to ner Security
Security to be Acquired Upon Exercise of Option, Warrant or Other Right to Acquire Security  Other Clescrib	De)
10. Business Combination Transa	action
Is this offering being made in connection with a business of	combination C Ves C No
transaction, such as a merger, acquisition or exchange off Clarification of Response (if Necessary)	er?
[ ]	
11. Minimum Investment	
Minimum investment accepted from any outside investor	000 USD
12. Sales Compensation	
Recipient	Recipient CRD Number None
Charles Vista, LLC	132650
(Associated) Broker or Dealer   None	(Associated) Broker or Dealer CRD Number None
Stand Address 1	Street Address 2
Street Address 1	Street Address 2
201 Edward Curry Avenue	Suite 103
	e/Province/Country ZIP/Postal Code EW YORK 10314
70.22	
State(s) of Solicitation All States Fo	oreign/Non-US
UTAH	
ILLINOIS	
NEW YORK	
INDIANA	
CONNECTICUT	
WEST VIRGINIA	
MINNESOTA	
ARIZONA	
MISSOURI	
CALIFORNIA	
KANSAS	
LOUISIANA	
WASHINGTON	
NEW JERSEY	
MICHIGAN	
ОНЮ	
ALASKA	
ALABAMA	
TEXAS	
COLORADO	
FLORIDA	
FLORIDA MARYLAND	

13. Offering and Sales Amounts
Total Offering Amount \$ 10000000 USD Indefinite  Total Amount Sold \$ 7928550 USD  Total Remaining to be Sold USD Indefinite
Clarification of Response (if Necessary)
14. Investors
Select if securities in the offering have been or may be sold to persons who do not qualify as accredited investors, Number of such non-accredited investors who already have invested in the offering  Regardless of whether securities in the offering have been or may be sold to persons who do not qualify as accredited investors, enter the total number of investors who already have invested in the offering:
15. Sales Commissions & Finders' Fees Expenses
Provide separately the amounts of sales commissions and finders' fees expenses, if any. If the amount of an expenditure is not known, provide an estimate and check the box next to the amount.
Sales Commissions \$ 1030711 USD Estimate
Finders' Fees \$ 0 USD Estimate
Clarification of Response (if Necessary)
10% Placement Agent Fee and 3% non-accountable expense.
16. Use of Proceeds
Provide the amount of the gross proceeds of the offering that has been or is proposed to be used for payments to any of the persons required to be named as executive officers, directors or promoters in response to Item 3 above. If the amount is unknown, provide an estimate and check the box next to the amount.
S USD Estimate
Clarification of Response (if Necessary)
Mr. Bacha, CEO, is under contract with the corporation and receives remuneration of \$12,000 per month for services.
Signature and Submission
orginataro arra oubrinocion
Please verify the information you have entered and review the Terms of Submission below before signing and clicking SUBMIT below to file this notice.
Terms of Submission
In submitting this notice, each Issuer named above is:

- Notifying the SEC and/or each State in which this notice is filed of the offering of securities
  described and undertaking to furnish them, upon written request, the information furnished to
  offerees
- Irrevocably appointing each of the Secretary of the SEC and, the Securities Administrator or other legally designated officer of the State in which the Issuer maintains its principal place of business and any State in which this notice is filed, as its agents for service of process, and agreeing that these persons may accept service on its behalf, of any notice, process or pleading, and further agreeing that such service may be made by registered or certified mail, in any Federal or state action, administrative proceeding, or arbitration brought against it in any place subject to the jurisdiction of the United States, if the action, proceeding or arbitration (a) arises out of any activity in connection with the offering of securities that is the subject of this notice, and (b) is founded, directly or indirectly, upon the provisions of: (i) the Securities Act of 1933, the Securities Exchange Act of 1934, the Trust Indenture Act of 1939, the Investment Company Act of 1940, or the Investment Advisers Act of 1940, or any rule or regulation under any of these statutes, or (ii) the laws of the State in which the issuer maintains its principal place of business or any State in which this notice is filed.
- Certifying that, if the issuer is claiming a Regulation D exemption for the offering, the issuer is not disqualified from relying on Regulation D for one of the reasons stated in Rule 505(b)(2)(iii) or Rule 506(d).

Each Issuer identified above has read this notice, knows the contents to be true, and has duly caused this notice to be signed on its behalf by the undersigned duly authorized person.

For signature, type in the signer's name or other letters or characters adopted or authorized as the signer's signature.

Issuer	Signature	Name of Signer	Title	Date
DelMar Pharmaceuticals, Inc.	/s/ Jeffrey Bacha	Jeffrey Bacha	Chief Executive Officer	2013-02-11